Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
68
days
Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma
AuthorsCallee Brooks; Leslie Mader; Kathryn Kennedy; Phyu Thin Naing; Salyka Sengsayadeth; Bhagirathbhai Dholaria; Adetola Kassim; Sarah Profitt; Muhamed Baljevic
Affiliations1. Department of Pharmacy, Vanderbilt University Medical Center, Nashville, USA; 2. Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA; 3. Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA
117
days
Sequential therapy with decitabine and an XPO-1 inhibitor followed by allogeneic hematopoietic stem cell transplantation in MDS with biallelic TP53 inactivation patients : a preliminary case series
AuthorsYanling Ren; Wei Lang; Yu Xu; Chen Mei; Xianbo Huang; Shasha Wang; Jiejing Qian; Hongyan Tong
Affiliations1. Department of Hematology, The First Affiliated Hospital, school of Medicine, Zhejiang University, Hangzhou, China
163
days
AAV-delivered miRNA-gated Cre circuits enable programmable gene activation in AFP-active liver tumor models
AuthorsXiaoting Zhang; Congcong Cao; Zeqi Huang; Dongde Wu; Tao Yin; Yuchen Liu; Jian Shen; Aolin Li; Shuofei Yang; Lei Nie
Affiliations1. Central Laboratory, Shenzhen Bao’an District Songgang People’s Hospital, Shenzhen, China; 2. Shenzhen Bao’an medical college of Guangdong Pharmaceutical University, Shenzhen, China; 3. Hubei Shizhen Laboratory, School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan, China; 4. Shenzhen Institute of Translational Medicine, Shenzhen Second People’s Hospital, Health Science Center, The First Affiliated Hospital of Shenzhen University, Shenzhen University, Shenzhen, China; 5. Department of Hepatobiliary and Pancreatic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 6. Department of Urology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China; 7. Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
202
days
Cellular adhesion-dependent 3D morphogenesis indicating brain tumor aggressiveness and chemosensitivity in spherical cavity culture
AuthorsThuy Huynh; Jieun Kim; Sarnai Amartumur; Inhee Choi; Ji Yeoun Lee; Luke P. Lee; Chaejeong Heo
Affiliations1. Department of Biophysics, Institute for Quantum Biophysics (IQB), Sungkyunkwan University, Suwon, Republic of Korea; 2. Department of Anatomy and Cell Biology, Seoul National University College of Medicine, Seoul, Republic of Korea; 3. Department of Life Science, Department of Chemistry, University of Seoul, Seoul, Republic of Korea; 4. Division of Pediatric Neurosurgery, Seoul National University Children’s Hospital, Seoul, Republic of Korea; 5. Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, Boston, USA; 6. Korea Biomedical Institute for Global Health Research and Technology (K-BIGHEART), Pohang University of Science and Technology (POSTECH), Gyeongbuk, Republic of Korea
151
days
The spatial and multi-omic landscape of Down syndrome leukemogenesis: moving beyond cellular heterogeneity
AuthorsEdoardo Peroni; Rosario Amato; Martina Bado; Mosè Favarato; Antonio Rosato
Affiliations1. Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy; 2. UOC Genetica Medica, Azienda Ospedaliera Universitaria Dulbecco, Università Magna Graecia, Catanzaro, Italy; 3. Lab. Immuno-Genetica, Dpt. Scienze della Salute, Università degli Studi “Magna Graecia” di Catanzaro, Catanzaro, Italy; 4. Dipartimento di Direzione Medica del Presidio Ospedaliero di Mestre, UOSD Genetica e Citogenetica, Venice, Italy; 5. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy
62
days
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual Meeting
AuthorsTiantian Zhang; Heng Jiang; Delong Liu
Affiliations1. Department of Internal Medicine, University of Central Florida, Pensacola, USA; 2. Chinese American Hematologist and Oncologist Network (CAHON), Milwaukee, USA; 3. Division of Hematology and Oncology, Department of Internal Medicine, Westchester Medical Center/New York Medical College, Valhalla, USA
146
days
Spatially resolved transcriptomic profiling of myelofibrosis spleen reveals compartment specific niche programs
AuthorsEdoardo Peroni; Marco Pizzi; Marco Basso; Alessandro Atanasio; Elisabetta Calistri; Michele Gottardi; Antonio Rosato
Affiliations1. Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padova, Italy; 2. Department of Medicine-DIMED, Surgical Pathology and Cytopathology Unit, Padua University Hospital, Padua, Italy; 3. Pharmacy, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 4. Onco-Hematology, Department of Oncology, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy; 5. Department of Surgery Oncology and Gastroenterology, University of Padova, Padova, Italy
67
days
Arsenic trioxide promotes a glue‑like interaction to drive STUB1-mediated NPM-ALK degradation in ALK + ALCL
AuthorsGuiming Li; Jun Wang; Shiguang Ye; Lixin Zhou; Yanli Sun; Bowen Li; Yunshuo Zhao; Yi Ding; Yu Zeng; Bin Xue; Guangming Wang; Fangce Wang; Xiu Luo; Aibin Liang; Ellen L. Weisberg; Wenjun Zhang; Wenchao Lu; Jing Yang
Affiliations1. Department of Hematology, Tongji Hospital, Frontier Science Center for Stem Cell Research, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai, China; 2. Lingang Laboratory, Shanghai, China; 3. Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China; 4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 5. Department of Medicine, Harvard Medical School, Boston, USA
61
days
Emerging venetoclax plus hypomethylating agent-based triplet regimens in newly diagnosed acute myeloid leukemia: updates from the 2025 ASH Annual Meeting
AuthorsHaibo Yu; Ting Shi; Hong-Hu Zhu
Affiliations1. Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China; 2. Chinese Institutes for Medical Research, Beijing, China; 3. Institute for Cancer, Chinese Institutes for Medical Research (CIMR), Beijing, China
106
days
Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion
AuthorsZhiru Gao; Linlin Yang; Linlin Wang
Affiliations1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days